| Source: |
| Type: |
| Drug dosage vs efficacy, and actual dosage number of research papers. |
| 8884- | MOR, | Morin Reactivates Nrf2 by Targeting Inhibition of Keap1 to Alleviate Deoxynivalenol-Induced Intestinal Oxidative Damage |
| - | in-vivo, | Nor, | NA |
| 8883- | MOR, | 5-FU, | Morin Mitigates 5-Fluorouracil-Induced Nephrotoxicity by Activating Nrf2/HO-1 and FXR, and Suppressing ERK/VCAM-1 and NF-κB Pathways |
| - | in-vivo, | Nor, | NA |
| 8882- | MOR, | Cisplatin, | Morin hydrate protects against cisplatin-induced testicular toxicity by modulating ferroptosis and steroidogenesis genes' expression and upregulating Nrf2/Heme oxygenase-1 |
| - | in-vivo, | Nor, | NA |
| 8879- | MOR, | doxoR, | Synergistic Effects of Morin and Doxorubicin Overcome Chemoresistance in Ovarian Cancer: Preclinical Insights From in vitro and in vivo Models |
| - | vitro+vivo, | Ovarian, | OVCAR-3 | - | NA, | Melanoma, | A2780S |
| 8876- | MOR, | SRF, | Synergic anticancer effects of morin hydrate and sorafenib delivered via polymeric iron oxide nanoparticles for the treatment of triple-negative breast cancer |
| - | in-vitro, | BC, | NA |
| 8922- | MP, | A Comprehensive Review of the Therapeutic Potential of Mucuna Pruriens |
| - | Review, | Park, | NA |
| 8921- | MP, | “To Bean or Not to Bean”: Therein lie the hype and the hope. Advice to people with Parkinson in my clinic about Mucuna pruriens |
| - | Review, | Park, | NA |
| 8920- | MP, | Therapeutic peptides of Mucuna pruriens L.: Anti‐genotoxic molecules against human hepatocellular carcinoma and hepatitis C virus |
| - | in-vitro, | Liver, | HepG2 | - | in-vitro, | HCC, | SMMC-7721 cell | - | in-vitro, | HCC, | QGY-7703 |
| 8919- | MP, | Antineoplastic Effects of Mucuna pruriens Against Human Colorectal Adenocarcinoma |
| - | in-vitro, | CRC, | COLO205 |
| 8918- | MP, | Cisplatin, | Mucuna pruriens (L.) DC chemo sensitize human breast cancer cells via downregulation of prolactin-mediated JAK2/STAT5A signaling |
| - | in-vitro, | BC, | T47D | - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MDA-MB-231 |
| 8776- | MSM, | Methylsulfonylmethane and boswellic acids versus glucosamine sulfate in the treatment of knee arthritis: Randomized trial |
| - | Trial, | Arthritis, | NA |
| 8780- | MSM, | Methylsulfonylmethane Induces Cell Cycle Arrest and Apoptosis, and Suppresses the Stemness Potential of HT-29 Cells |
| - | in-vitro, | CRC, | HT-29 |
| 8770- | MSM, | Cisplatin, | Methylsulfonylmethane (MSM) Mitigates Cisplatin-Induced Early Oxidative Testicular Dysfunction Through Modulation of Antioxidant Defense and GPX4 Response |
| - | in-vivo, | Nor, | NA |
| 3846- | MSM, | Accumulation of methylsulfonylmethane in the human brain: identification by multinuclear magnetic resonance spectroscopy |
| - | Human, | Nor, | NA |
| 3847- | MSM, | Methylsulfonylmethane: Applications and Safety of a Novel Dietary Supplement |
| - | Review, | Arthritis, | NA |
| 3849- | MSM, | Beauty from within: Oral administration of a sulfur-containing supplement methylsulfonylmethane improves signs of skin ageing |
| - | Human, | Nor, | NA |
| 8805- | MT/VAE, | Chemo, | Mistletoe extract in patients with advanced pancreatic cancer: Health-related quality of life in a double-blind, randomized, placebo-controlled trial (MISTRAL) |
| - | Trial, | PC, | NA |
| 8802- | MT/VAE, | Pharmakokinetics of Mistletoe Lectins after Intravenous Application of a Mistletoe Product in Healthy Subjects |
| - | Trial, | Nor, | NA |
| 8800- | MT/VAE, | Phase I Trial of Intravenous Mistletoe Extract in Advanced Cancer |
| - | Trial, | Var, | NA |
| 7342- | MT/VAE, | Hne, | Minor regression and long-time survival (56 months) in a patient with malignant pleural mesothelioma under Viscum album and Helleborus niger extracts—a case report |
| - | Case Report, | MM, | NA |
| 8943- | MushCha, | Continuous intake of the Chaga mushroom (Inonotus obliquus) aqueous extract suppresses cancer progression and maintains body temperature in mice |
| - | in-vivo, | Lung, | NA |
| 8935- | MushCha, | Chaga Mushroom Triterpenoids Inhibit Dihydrofolate Reductase and Act Synergistically with Conventional Therapies in Breast Cancer |
| - | in-vitro, | BC, | SkBr3 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF-10AT |
| 8936- | MushCha, | Inonotus obliquus polysaccharides induces apoptosis of lung cancer cells and alters energy metabolism via the LKB1/AMPK axis |
| - | vitro+vivo, | Lung, | LLC1 |
| 8937- | MushCha, | Effects of Inonotus obliquus Polysaccharides on Proliferation, Invasion, Migration, and Apoptosis of Osteosarcoma Cells |
| - | in-vitro, | OS, | MG63 | - | in-vitro, | OS, | U2OS |
| 8938- | MushCha, | Bioactivity-based analysis and chemical characterization of cytotoxic constituents from Chaga mushroom (Inonotus obliquus) that induce apoptosis in human lung adenocarcinoma cells |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H1299 | - | in-vitro, | Lung, | Calu-6 |
| 8940- | MushCha, | Anticancer activity of subfractions containing pure compounds of Chaga mushroom (Inonotus obliquus) extract in human cancer cells and in Balbc/c mice bearing Sarcoma-180 cells |
| - | in-vivo, | sarcoma, | S180 | - | in-vitro, | Lung, | A549 | - | in-vitro, | GC, | AGS | - | in-vitro, | BC, | MCF7 |
| 8962- | mushLions, | Unveiling the role of erinacines in the neuroprotective effects of Hericium erinaceus: a systematic review in preclinical models |
| - | Review, | AD, | NA |
| 8945- | mushLions, | The Acute and Chronic Effects of Lion’s Mane Mushroom Supplementation on Cognitive Function, Stress and Mood in Young Adults: A Double-Blind, Parallel Groups, Pilot Study |
| - | Trial, | Nor, | NA |
| 8946- | mushLions, | Prevention of Early Alzheimer's Disease by Erinacine A-Enriched Hericium erinaceus Mycelia Pilot Double-Blind Placebo-Controlled Study |
| - | Trial, | AD, | NA |
| 8947- | mushLions, | Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial |
| - | Trial, | AD, | NA |
| 8948- | mushLions, | Reduction of depression and anxiety by 4 weeks Hericium erinaceus intake |
| - | Trial, | AD, | NA |
| 8949- | mushLions, | Hericium erinaceus Improves Mood and Sleep Disorders in Patients Affected by Overweight or Obesity: Could Circulating Pro-BDNF and BDNF Be Potential Biomarkers? |
| - | Trial, | Obesity, | NA |
| 8950- | mushLions, | Absolute Bioavailability, Tissue Distribution, and Excretion of Erinacine S in Hericium erinaceus Mycelia |
| - | in-vivo, | AD, | NA |
| - | vitro+vivo, | CRC, | DLD1 |
| 2484- | mushLions, | Neurotrophic and Neuroprotective Effects of Hericium erinaceus |
| - | Review, | Stroke, | NA | - | Review, | AD, | NA | - | Review, | Park, | NA |
| 9303- | MushMait, | A phase I/II trial of a polysaccharide extract from Grifola frondosa (Maitake mushroom) in breast cancer patients: immunological effects |
| - | Trial, | BC, | NA |
| 9306- | MushMait, | Maitake (D fraction) mushroom extract induces apoptosis in breast cancer cells by BAK-1 gene activation |
| - | in-vitro, | BC, | MCF7 |
| 9308- | MushMait, | Maitake mushroom supplementation modulates upper respiratory symptoms and immune responses in healthy adults: a randomized, double-blind, placebo-controlled trial |
| - | Trial, | Nor, | NA |
| 9309- | MushMait, | Maitake Mushroom (Grifola frondosa) Enhances Cognitive Function in Healthy Older Japanese: A Randomized, Double-Blind, Placebo-Controlled Trial |
| - | Trial, | Nor, | NA |
| 2931- | NAD, | NAD+ Repletion Rescues Female Fertility during Reproductive Aging |
| - | in-vivo, | Nor, | NA |
| 2933- | NAD, | Nicotinamide mononucleotide (NMN) as an anti-aging health product – Promises and safety concerns |
| - | Review, | Nor, | NA | - | NA, | AD, | NA | - | NA, | Diabetic, | NA | - | NA, | Stroke, | NA | - | NA, | LiverDam, | NA | - | NA, | Park, | NA |
| - | Trial, | Nor, | NA |
| 2937- | NAD, | High-Dosage NMN Promotes Ferroptosis to Suppress Lung Adenocarcinoma Growth through the NAM-Mediated SIRT1-AMPK-ACC Pathway |
| - | in-vitro, | Lung, | A549 |
| 5786- | NAD, | Therapeutic potential of NAD-boosting molecules: the in vivo evidence |
| - | Review, | Nor, | NA |
| 5598- | NaHCO3, | Bicarbonate Increases Tumor pH and Inhibits Spontaneous Metastases |
| - | in-vivo, | BC, | MDA-MB-231 |
| 5599- | NaHCO3, | Acidity generated by the tumor microenvironment drives local invasion |
| - | in-vivo, | BC, | MDA-MB-231 | - | in-vitro, | CRC, | HCT116 |
| 5606- | NaHCO3, | Effects of Alkalization Therapy on Chemotherapy Outcomes in Metastatic or Recurrent Pancreatic Cancer |
| - | Trial, | PC, | NA |
| 5605- | NaHCO3, | A nonrandomized cohort and a randomized study of local control of large hepatocarcinoma by targeting intratumoral lactic acidosis |
| - | Trial, | HCC, | NA |
| 5602- | NaHCO3, | immuno, | Immunotherapy Enhancement by Targeting Extracellular Tumor pH in Triple-Negative Breast Cancer Mouse Model |
| - | in-vivo, | BC, | 4T1 |
| 1805- | NarG, | Naringenin suppresses epithelial ovarian cancer by inhibiting proliferation and modulating gut microbiota |
| - | in-vitro, | Ovarian, | A2780S | - | in-vivo, | NA, | NA |
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include :
-low or high Dose
-format for product, such as nano of lipid formations
-different cell line effects
-synergies with other products
-if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:1114 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid